{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:03:25Z","timestamp":1790517805284,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114189","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T22:11:47Z","timestamp":1644876707000},"page":"114189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Influenza-existing drugs and treatment prospects"],"prefix":"10.1016","volume":"232","author":[{"given":"Avishak","family":"Sarker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhuang","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoduo","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2022.114189_bib1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.apsb.2015.07.006","article-title":"New small-molecule drug design strategies for fighting resistant influenza A","volume":"5","author":"Shen","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4049\/jimmunol.1801010","article-title":"Influenza pathogenesis: the effect of host factors on severity of disease","volume":"202","author":"Gounder","year":"2019","journal-title":"J.\u00a0Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114189_bib3","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2165\/11537960-000000000-00000","article-title":"Drugs in development for influenza","volume":"70","author":"Boltz","year":"2010","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114189_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173582","article-title":"Identification of small molecule inhibitors for influenza a virus using in silico and in\u00a0vitro approaches","volume":"12","author":"Makau","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ejmech.2022.114189_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s12098-020-03214-1","article-title":"Influenza","volume":"87","author":"Dharmapalan","year":"2020","journal-title":"Indian J. Pediatr."},{"issue":"12","key":"10.1016\/j.ejmech.2022.114189_bib6","first-page":"2596","article-title":"Readiness for responding to a severe pandemic 100 Years after 1918","volume":"187","author":"Jester","year":"2018","journal-title":"Am. J. Epidemiol."},{"issue":"28","key":"10.1016\/j.ejmech.2022.114189_bib7","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1073\/pnas.0904991106","article-title":"Dating the emergence of pandemic influenza viruses","volume":"106","author":"Smith","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.ejmech.2022.114189_bib8","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1073\/pnas.1324197111","article-title":"Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus","volume":"111","author":"Worobey","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.ejmech.2022.114189_bib9","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/S0264-410X(03)00075-6","article-title":"The role of antivirals in the control of influenza","volume":"21","author":"Monto","year":"2003","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114189_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/v13040624","article-title":"Antivirals targeting the surface glycoproteins of influenza virus: mechanisms of action and resistance","volume":"13","author":"Bai","year":"2021","journal-title":"Viruses"},{"issue":"16","key":"10.1016\/j.ejmech.2022.114189_bib11","doi-asserted-by":"crossref","first-page":"7368","DOI":"10.1128\/JVI.00898-16","article-title":"Identification and characterization of influenza virus entry inhibitors through dual myxovirus high-throughput screening","volume":"90","author":"Weisshaar","year":"2016","journal-title":"J.\u00a0Virol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2022.114189_bib12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.ejmech.2022.114189_bib13","doi-asserted-by":"crossref","first-page":"b5106","DOI":"10.1136\/bmj.b5106","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis","volume":"339","author":"Jefferson","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2022.114189_bib14","unstructured":"Centers for disease control and prevention,\" [Online]. Available: https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm. [Accessed 21 05 2021]."},{"key":"10.1016\/j.ejmech.2022.114189_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1741-7015-10-104","article-title":"New treatments for influenza","volume":"10","author":"Barik","year":"2012","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmech.2022.114189_bib16","first-page":"Doc04","article-title":"Influenza viruses - antiviral therapy and resistance","volume":"5","author":"Duwe","year":"2017","journal-title":"GMS Infect. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2022.114189_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199936001-00001","article-title":"Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers","volume":"36","author":"Cass","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"9698","key":"10.1016\/j.ejmech.2022.114189_bib18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(09)61804-3","article-title":"Possible harms of oseltamivir--a call for urgent action","volume":"374","author":"Jefferson","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114189_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/EDE.0b013e3181a3d3f6","article-title":"Oseltamivir and abnormal behaviors: true or not?","volume":"20","author":"Yorifuji","year":"2009","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1586\/17476348.2016.1126182","article-title":"Oseltamivir for influenza infection in children: risks and benefits","volume":"10","author":"Esposito","year":"2016","journal-title":"Expet Rev. Respir. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neulet.2008.04.011","article-title":"Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex","volume":"438","author":"Yoshino","year":"2008","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.9758\/cpn.2015.13.2.209","article-title":"Psychiatric symptoms in a patient with influenza A (H1N1) treated with oseltamivir (Tamiflu): a case report","volume":"13","author":"Jeon","year":"2015","journal-title":"Clin. Psychopharmacol. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/ane.12629","article-title":"The mechanisms of sudden-onset type adverse reactions to oseltamivir","volume":"135","author":"Hama","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejmech.2022.114189_bib24","doi-asserted-by":"crossref","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018","volume":"175","author":"Takashita","year":"2020","journal-title":"Antivir. Res."},{"issue":"20","key":"10.1016\/j.ejmech.2022.114189_bib25","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01200-09","article-title":"Zanamivir-resistant influenza viruses with a novel neuraminidase mutation","volume":"83","author":"Hurt","year":"2009","journal-title":"J.\u00a0Virol."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114189_bib26","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12929-019-0567-0","article-title":"Development of effective anti-influenza drugs: congeners and conjugates - a review","volume":"26","author":"Shie","year":"2019","journal-title":"J.\u00a0Biomed. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1134\/S0026893320020168","article-title":"Design of an efficient inhibitor for the influenza A virus M2 ion channel","volume":"54","author":"Vorobjev","year":"2020","journal-title":"Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114189_bib29","series-title":"Influenza Antiviral Medications: Summary for Clinicians","year":"2019"},{"issue":"12","key":"10.1016\/j.ejmech.2022.114189_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrd2400","article-title":"The war against influenza: discovery and development of sialidase inhibitors","volume":"6","author":"von Itzstein","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2022.114189_bib31","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold?","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"Pt 4","key":"10.1016\/j.ejmech.2022.114189_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1099\/vir.2008.007260-0","article-title":"High prevalence of amantadine resistance among circulating European porcine influenza A viruses","volume":"90","author":"Krumbholz","year":"2009","journal-title":"J.\u00a0Gen. Virol."},{"issue":"18","key":"10.1016\/j.ejmech.2022.114189_bib33","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1073\/pnas.0902548106","article-title":"Mechanism of drug inhibition and drug resistance of influenza A M2 channel","volume":"106","author":"Pielak","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.bmc.2009.11.047","article-title":"Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus","volume":"18","author":"Zarubaev","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114189_bib35","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1128\/AAC.00731-09","article-title":"CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract","volume":"53","author":"Koyama","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114189_bib36","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1128\/AAC.01311-09","article-title":"Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration","volume":"54","author":"Kubo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114189_bib37","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1128\/AAC.01755-09","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection","volume":"54","author":"Sugaya","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114189_bib38","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114189_bib39","doi-asserted-by":"crossref","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antivir. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"17","key":"10.1016\/j.ejmech.2022.114189_bib41","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMc0905290","article-title":"Use of ribavirin to treat influenza","volume":"361","author":"Chan-Tack","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114189_bib42","series-title":"Baloxavir (Xofluza): A New Antiviral Drug for the Flu","author":"Kuritzkes","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114189_bib43","unstructured":"Antiviral drugs for influenza for 2020-2021. (2020). Med. Lett. Drugs Ther., 62(1610), 169-172."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib44","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"issue":"15","key":"10.1016\/j.ejmech.2022.114189_bib45","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2022.114189_bib46","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2022.114189_bib47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3390\/v4071144","article-title":"Influenza virus-mediated membrane fusion: determinants of hemagglutinin fusogenic activity and experimental approaches for assessing virus fusion","volume":"4","author":"Hamilton","year":"2012","journal-title":"Viruses"},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2022.114189_bib48","first-page":"S149","article-title":"Novel hemagglutinin-based influenza virus inhibitors","volume":"5","author":"Shen","year":"2013","journal-title":"J.\u00a0Thorac. Dis."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015874","article-title":"Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol","volume":"6","author":"Teissier","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114189_bib50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ejmech.2022.114189_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nbt.1638","article-title":"Identification of influenza A nucleoprotein as an antiviral target","volume":"28","author":"Kao","year":"2010","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114189_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2235","article-title":"Influenza nucleoprotein: promising target for antiviral chemotherapy","volume":"23","author":"Cianci","year":"2012","journal-title":"Antivir. Chem. Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114189_bib53","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.02335-12","article-title":"Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus","volume":"57","author":"Lejal","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114189_bib54","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1021\/jm2013503","article-title":"Design, synthesis, and in\u00a0vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein","volume":"55","author":"Cheng","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114189_bib55","series-title":"Developing DAS181 for Influenza and Other Infections","author":"Biopharma","year":"2018"},{"issue":"7083","key":"10.1016\/j.ejmech.2022.114189_bib56","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/440435a","article-title":"Avian flu: influenza virus receptors in the human airway","volume":"440","author":"Shinya","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ejmech.2022.114189_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.antiviral.2008.06.003","article-title":"Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N","volume":"80","author":"Smee","year":"2008","journal-title":"Antivir. Res."},{"issue":"8","key":"10.1016\/j.ejmech.2022.114189_bib58","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.47.8.2518-2525.2003","article-title":"Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin","volume":"47","author":"O'Keefe","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.ejmech.2022.114189_bib59","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.ejmech.2022.114189_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007428","article-title":"Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration","volume":"14","author":"Jia","year":"2018","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.ejmech.2022.114189_bib62","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/17476348.2020.1730180","article-title":"Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief","volume":"14","author":"Ishaqui","year":"2020","journal-title":"Expet Rev. Respir. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib63","first-page":"24","article-title":"Antiviral natural products and herbal medicines","volume":"4","author":"Lin","year":"2014","journal-title":"J.\u00a0Tradit. Compl. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2022.114189_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2005.06.010","article-title":"Antiviral effect of catechins in green tea on influenza virus","volume":"68","author":"Song","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114189_bib65","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3762\/bjoc.9.182","article-title":"Bioinspired total synthesis of katsumadain A by organocatalytic enantioselective 1,4-conjugate addition","volume":"9","author":"Wang","year":"2013","journal-title":"Beilstein J. Org. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2022.114189_bib66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.phytochem.2009.06.003","article-title":"Elderberry flavonoids bind to and prevent H1N1 infection in\u00a0vitro","volume":"70","author":"Roschek","year":"2009","journal-title":"Phytochemistry"},{"issue":"4","key":"10.1016\/j.ejmech.2022.114189_bib67","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.foodchem.2009.09.011","article-title":"Curcumin inhibits influenza virus infection and haemagglutination activity","volume":"119","author":"Chen","year":"2010","journal-title":"Food Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib68","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12906-018-2173-1","article-title":"Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines","volume":"18","author":"Liu","year":"2018","journal-title":"BMC Compl. Alternative Med."},{"issue":"1","key":"10.1016\/j.ejmech.2022.114189_bib69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12906-017-1612-8","article-title":"Anti-influenza virus activity of extracts from the stems of Jatropha multifida Linn. collected in Myanmar","volume":"17","author":"Shoji","year":"2017","journal-title":"BMC Compl. Alternative Med."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:41:04Z","timestamp":1759329664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":69,"alternative-id":["S0223523422000915"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114189","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influenza-existing drugs and treatment prospects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114189"}}